UK AI News

UK AI News — July 2026 Digest

Fri, 31 Jul 2026 00:00:00 GMT

July was a big month for UK AI investment, and the headline number came from Cambridge.

The month in brief

The standout was CuspAI, which raised around £334M to scale its AI system for discovering new materials, one of the largest UK AI rounds of the year and an early test of the government's Sovereign AI Venture Fund. It fits a pattern we keep coming back to: some of the most ambitious UK AI money is going into science, not chatbots.

On the public-sector side, NHS England set out its widest AI rollout yet, spanning a triage tool in the NHS App, ambient voice notetaking for clinicians, and Microsoft Copilot for more than half a million staff. The promise is shorter waiting times. The test, as ever, is whether the tools are reliable enough to earn the trust the rollout assumes.

Also worth your time

Beyond the stories we covered in full, a few more caught our eye. Sovereign and defence AI had a strong month, funding kept flowing into robotics and physical AI, and the public sector put real money behind academic research. You will find those below, each with a link to the original source.

That is July. August tends to be quieter, but the autumn usually brings the bigger funding announcements, so we will see.

CuspAI raises £334M to design new materials with AI

Fri, 24 Jul 2026 00:00:00 GMT

CuspAI, a Cambridge company using AI to discover new materials, has raised around £334M, or roughly $450M, in one of the largest UK AI rounds so far this year. The round was led by the venture firms Kleiner Perkins and NEA, and its backers include Britain's Sovereign AI Venture Fund, the government-backed vehicle set up to take stakes in strategically important AI companies.

The money is meant to scale what CuspAI calls its materials foundry: a system that searches for and designs molecular structures with specific properties, starting with materials that capture carbon. The pitch is that AI can shortcut the slow laboratory work of trying one candidate compound after another, proposing promising structures for chemists to make and test.

For the UK, the round lands two ways. It is a vote of confidence in Cambridge as a centre for AI applied to physical science, and the presence of the Sovereign AI Venture Fund makes it an early, visible test of the government's willingness to co-invest alongside private capital in companies it considers strategic. It also follows a pattern we noted in our coverage of Isomorphic Labs, another well-funded UK company pointing AI at science rather than chatbots.

The technology rests on a foundation model, a large general-purpose system trained once on a broad body of data and then adapted to specific tasks. Where a language model learns the patterns of text, CuspAI's models learn the patterns of chemistry, using machine learning to predict how a proposed material will behave before anyone makes it. Whether that translates into materials working at industrial scale is the harder question the funding is meant to answer, and one that will take years rather than months.

NHS England expands AI across triage, notes, and staff tools

Sat, 04 Jul 2026 00:00:00 GMT

NHS England has announced a national expansion of AI across the health service, covering three main areas: an AI triage tool built into the NHS App that points patients toward a GP, pharmacy, A&E, or self-care; ambient voice tools that draft clinical notes from a conversation so staff spend less time typing; and Microsoft Copilot for more than 500,000 NHS staff. The work is funded from a £10bn technology budget over three years, part of the government's 10-Year Health Plan.

The numbers NHS England cites are the reason it matters. It says an early trial of the triage tool cut GP phone-queue calls by 29%, that ambient voice tools gave clinicians about a quarter more patient-facing time, and that one hospital pilot saved 47 minutes per clinician shift. If those hold up as the tools reach millions of patients, the effect on waiting times could be larger than any single new treatment.

The context is that this is one of the biggest public-sector AI deployments anywhere, and it arrives with real questions attached. Ambient voice tools rely on speech recognition and machine learning that can mishear or misrecord, and a triage tool that routes patients carries obvious risks if it gets a decision wrong. NHS England says clinicians stay responsible for decisions and that the tools assist rather than replace them, which is the line regulators and the public will watch closely as the rollout widens through 2027 and 2028.

Worth noting for anyone following the technology: the more advanced end of this, where an AI agent takes actions across systems on a clinician's behalf rather than simply drafting text, is not yet what is being deployed at scale here. Most of what is rolling out now is assistance, not autonomy, and the distinction matters for how much trust to place in it.

Isomorphic Labs raises $2.1B to turn AlphaFold into medicines

Tue, 12 May 2026 00:00:00 GMT

Isomorphic Labs has raised $2.1B, or roughly £1.6B, in its first outside funding round, the London company said. The round was led by Thrive Capital, with its parent Alphabet and the venture arm GV also taking part, and values Isomorphic as one of the best-funded AI drug-discovery companies in Europe.

The size of the round is the story. Isomorphic has never raised external money before, having been funded from inside Alphabet since it was spun out of Google DeepMind in 2021. A $2.1B first cheque is less a bet on a young startup than a bet that AlphaFold, the protein-structure system that won its DeepMind creators a share of the 2024 Nobel Prize in Chemistry, can be turned into a working drug pipeline. Isomorphic says the money will fund its own drug programmes and its partnerships with the pharmaceutical firms Eli Lilly and Novartis.

For the UK, it is a rare example of a home-grown biotech built on frontier AI rather than one bolting AI onto an existing pipeline. It also keeps a piece of DeepMind's most celebrated research commercialising in London rather than crossing the Atlantic, at a moment when much of the UK's AI talent is being courted by better-funded American labs.

The science leans on a foundation model, a large general-purpose system trained once on a vast body of data and then adapted to many tasks. Where AlphaFold predicted the shape a protein folds into, Isomorphic's newer models aim to predict how a candidate drug molecule and a target protein will interact, the step that decides whether a drug works. Getting that right through machine learning could cut years off the slow, expensive trial-and-error of the lab, though no AI-designed drug from the company has yet been proven in patients.